EP Patent

EP2481411A1 — Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib

Assigned to Ratiopharm GmbH · Expires 2012-08-01 · 14y expired

What this patent protects

The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms.

USPTO Abstract

The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP2481411A1
Jurisdiction
EP
Classification
—
Expires
2012-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Ratiopharm GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.